MYCN is a bHLH transcription factor that functions as a master regulator of oncogenic gene expression, particularly in neural crest-derived cancers. As a sequence-specific DNA-binding transcription factor, MYCN heterodimerizes with MAX protein to activate promoters of genes involved in ribosome biogenesis, protein synthesis, and cell proliferation, while simultaneously repressing neuronal differentiation genes 1. Beyond canonical transcriptional activation, MYCN possesses RNA-binding capacity through its conserved MYCBoxI domain, enabling association with the nuclear exosome and intronic transcripts to regulate RNA metabolism and influence cell cycle progression 2. MYCN amplification occurs in approximately 25% of neuroblastomas and represents the most robust genetic marker of high-risk disease and poor prognosis 3. MYCN-driven oncogenesis extends beyond neuroblastoma to aggressive retinoblastoma subtypes, where it promotes de-differentiation and activates MYC/E2F and mTORC1 signaling pathways 4. MYCN also functions in neuroendocrine prostate cancer through a positive feedback loop with the RNA-binding protein ELAVL3 5. Therapeutic strategies targeting MYCN include disrupting its recruitment of the super elongation complex, inhibiting eIF4A1-mediated translation of MYCN mRNA via its 5' UTR, and combining WDR5 and G9a inhibitors to simultaneously block MYCN's transcriptional activation and repression functions 6, 7, 1.